Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Jens Fischer

Stefan Seeber

Joerg Moelleken

Georg Fertig

Tilman Schlothauer

Pablo Umana

Valeria Lifke

Christian Klein

Guy Georges

Stefan Dengl

Georg Tiefenthaler

Ekkehard Moessner

Joerg Thomas Regula

Klaus Kaluza

Hubert Kettenberger

Viktor Levitski

Ralf Hosse

Pablo Umaña

Sabine Imhof-Jung

Stefan Klostermann

Sebastian Fenn

Thomas U Hofer

Michael Brandt

Joerg Benz

Thomas Emrich

Johannes Auer

Sonja Offner

Achal Mukundrao Pashine

Martin Bader

Gregor Jordan

Christian Schantz

Laurent Lariviere

Thomas Friess

Claudio Sustmann

Sabine Hoves

Josef Endl

Alexander Bujotzek

Maximiliane Koenig

Josef Platzer

Meher Majety

Adrian Zwick

Mario Perro

Laura Codarri-Deak

Ildiko Wuensche

Anton Jochner

Stefan Lorenz

Shu Feng

Valeria Runza

Martin Schaefer

Claudia Kirstenpfad

Lydia Jasmin Duerner

Daigen Xu

Maria Viert

Siok Wan Gan

Wei Shiong Adrian Ho

Michael Gertz

Runyi Adeline Lam

Barbara Weiser

Laura Codarri Deak

Francesca Ros

Peter Kern

Esther Koenigsberger

Stefan Jenewein

Andreas Hinz

Anne-Claire Zagdoun

Laura Deak Codarri

Ben-Fillippo Krippendorff

Patrick Alexander Aaron Weber

Eileen Samy

Oliver Ploettner

Achal Pashine

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.

Stabilized immunoglobulin domains

The present invention relates to anti-HLA-G antibodies and methods of using the same.

Anti-HLA-G antibodies and methods of use thereof

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

Anti-HLA-G antibodies and use thereof

The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specifically binding to PD1 and LAG3

Herein is reported a method for the determination of the simultaneous binding of a bispecific antibody to a first and a second antigen comprising the steps of a) incubating a cell expressing cell-membrane bound FRET-donor-tagged first antigen and FRET-acceptor-tagged second antigen with the bispecific antibody, and b) determining the simultaneous binding of the bispecific antibody by determining the energy transfer from the FRET-donor to the FRET-acceptor.

Cellular based fret assay for the determination of simultaneous binding

The invention provides anti-TPBG antibodies and methods of using the same.

Anti-TPBG antibodies and methods of use

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.

TNFa-IL-17 bispecific antibodies

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Interleukin-10 fusion proteins and uses thereof

The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies against human TWEAK and human IL17 and uses thereof

Interleukin-10 fusion proteins

Growing community of inventors

Weilheim in Oberbayern, Germany

Jens Fischer